Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 31, Supplement—April 2025
SUPPLEMENT ISSUE
Supplement
Successful Transition to Whole-Genome Sequencing and Bioinformatics to Identify Invasive Streptococcus spp. Drug Resistance, Alaska, USA
Karen M. Miernyk
, Sopio Chochua, Ben Metcalf, Alisa Reasonover, and Brenna Simons-Petrusa
, Sopio Chochua, Ben Metcalf, Alisa Reasonover, and Brenna Simons-Petrusa
Table 3
Initial phenotypic testing results for 293 Streptococcus pneumoniae isolates used for whole-genome sequencing workflow validation in Alaska in study to identify invasive Streptococcus spp. drug resistance, 1986–2021
| Antimicrobial drugs | Total no. isolates | No. susceptible isolates | No. nonsusceptible isolates |
|---|---|---|---|
| Cefotaxime | 75 | 38* | 37* |
| Ceftriaxone | 278 | 271* | 26* |
| Chloramphenicol | 293 | 278 | 15 |
| Clindamycin | 274 | 248 | 26 |
| Erythromycin | 291 | 221 | 70 |
| Levofloxacin | 277 | 276 | 1 |
| Linezolid | 271 | 271 | 0 |
| Meropenem | 278 | 247 | 31 |
| Penicillin | 293 | 218* | 75* |
| Rifampin | 246 | 222 | 24 |
| Quinupristin/dalfopristin | 275 | 262 | 13 |
| Tetracycline | 87 | 49 | 38 |
| Trimethoprim/sulfamethoxazole | 286 | 175 | 111 |
| Vancomycin | 293 | 293 | 0 |
*Determined by using the Clinical and Laboratory Standards Institute (https://www.clsi.org) breakpoint for meningitis cases.
Page created: March 21, 2025
Page updated: April 14, 2025
Page reviewed: April 14, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.